Detection of PitNET Tissue During TSS Using Bevacizumab-800CW

NCT04212793 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Pituitary Tumor
Pituitary Adenoma
Pituitary Macroadenoma

Interventions

DRUG: Bevacizumab-IRDye800CW
DEVICE: Molecular Fluorescence Endoscopy platform

Sponsor

University Medical Center Groningen